140. Dorabe syndrome Clinical trials / Disease details

Clinical trials : 116 / Drugs : 65 - (DrugBank : 17) / Drug target genes : 50 - Drug target pathways : 64

22 trials found

diseases per page:

Showing 1 to 10 of 22 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05485831 (ClinicalTrials.gov)	April 2023	29/7/2022	Epidyolex® in Lennox Gastaut and Dravet Syndrome: an Observational Study in ITALY	Observational, Prospective, Multicenter Study of Epidyolex® (CannabidiolCBD 100 mg/ml) Oral Solution ...	Lennox Gastaut Syndrome;Dravet Syndrome	Drug: Epidiolex 100 mg/mL Oral Solution	Jazz Pharmaceuticals	Evidilya S.r.l.	Not yet recruiting	6 Years	17 Years	All	70		Italy
2	NCT05044819 (ClinicalTrials.gov)	July 7, 2021	30/8/2021	Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol ...	A Long-term Safety Study to Assess the Potential for Chronic Liver Injury in Participants Treated Wi ...	Lennox Gastaut Syndrome;Dravet Syndrome;Tuberous Sclerosis Complex	Drug: Cannabidiol	Jazz Pharmaceuticals	NULL	Recruiting	1 Year	N/A	All	150	Phase 4	United States
3	NCT04485104 (ClinicalTrials.gov)	May 19, 2021	21/7/2020	Assessment of Adjunctive CannabidiolOral Solution (GWP42003-P) in Children With Tuberous Sclerosis C ...	An Open-label, Single-arm Study to Assess the Safety, Pharmacokinetics, and Efficacy of Adjunctive C ...	Seizure in Participants With Tuberous Sclerosis Complex;Seizure in Participants With Dravet Syndrome ...	Drug: GWP42003-P	Jazz Pharmaceuticals	NULL	Recruiting	1 Month	23 Months	All	27	Phase 3	United States
4	NCT04611438 (ClinicalTrials.gov)	March 30, 2020	16/9/2019	Research on Cognitive Effect of Cannabidiolon Dravet Syndrome and Lennox-Gastaut SyndromeGastaut Syn ...	A Prospective Multi-Center Single-Arm Clinical Trial on Cognitive Effect of Cannabidiol(CBD-OS®) on ...	Dravet Syndrome;Lennox Gastaut Syndrome	Drug: Cannabidiol	Yonsei University	NULL	Recruiting	2 Years	18 Years	All	107	Phase 3	Korea, Republic of
5	NCT03467113 (ClinicalTrials.gov)	January 19, 2018	30/1/2018	A Study to Assess the Safety and Tolerability of ZX008 in Children and Young Adults With Dravet Synd ...	An Open-Label Trial to Assess the Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution in Comb ...	Dravet Syndrome;Lennox Gastaut Syndrome	Drug: ZX008 0.2 to 0.8 mg/kg/day;Drug: Cannabidiol	Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.	NULL	Completed	2 Years	18 Years	All	9	Phase 1	United States
6	NCT02318563 (ClinicalTrials.gov)	December 30, 2017	12/12/2014	CannabidiolOral Solution as an Adjunctive Therapy for Treatment of Participants With Inadequately Co ...	A Multicenter, Randomized, Double-blind, Placebo- Controlled, Interventional Study to Assess the Saf ...	Dravet Syndrome	Drug: Cannabidiol Oral Solution;Drug: Placebo Solution	INSYS Therapeutics Inc	NULL	Withdrawn	1 Year	30 Years	All	0	Phase 3	NULL
7	NCT02815540 (ClinicalTrials.gov)	February 16, 2017	20/6/2016	The Effects of Cannabidiol(CBD) on Electrical and Autonomic Cardiac Function in Children With Severe ...	The Effects of Cannabidiol (CBD) on Electrical and Autonomic Cardiac Function in Children	Lennox-Gastaut Syndrome;Dravet Syndrome	Procedure: 12-Lead ECG;Drug: Cannabidiol	Gillette Children's Specialty Healthcare	NULL	Terminated	2 Years	30 Years	All	2	Phase 1/Phase 2	United States
8	EUCTR2014-001834-27-NL (EUCTR)	09/09/2015	18/06/2015	An open label study of the safety of cannabidiol(GWP42003-P) in children and adults with Dravet or L ...	An open label extension study to investigate the safety of cannabidiol(GWP42003-P; CBD) in children ...	Dravet Syndrome (DS) or Lennox-Gastaut Syndrome (LGS) MedDRA version: 20.0;Level: PT;Classification ...	Trade Name: CBD - Oral Solution, is known as Epidiolex, and is the approved name in the USA. Product N ...	GW Research Ltd	NULL	Not Recruiting			Female: yes Male: yes	680	Phase 3	United States;France;Spain;Poland;Australia;Israel;Netherlands;United Kingdom
9	EUCTR2014-001834-27-FR (EUCTR)	03/09/2015	20/07/2015	An open label study of the safety of cannabidiol(GWP42003-P) in children and adults with Dravet or L ...	An open label extension study to investigate the safety of cannabidiol(GWP42003-P; CBD) in children ...	Dravet Syndrome (DS) or Lennox-Gastaut Syndrome (LGS) MedDRA version: 18.0;Level: PT;Classification ...	Product Name: Cannabidiol (CBD) Product Code: GWP42003-P INN or Proposed INN: N/A Other descriptive name ...	GW Research Ltd	NULL	Not Recruiting			Female: yes Male: yes	530	Phase 3	United States;France;Spain;Poland;Israel;Netherlands;United Kingdom
10	EUCTR2014-001834-27-PL (EUCTR)	18/08/2015	14/05/2015	An open label study of the safety of cannabidiol(GWP42003-P) in children and adults with Dravet or L ...	An open label extension study to investigate the safety of cannabidiol(GWP42003-P; CBD) in children ...	Dravet Syndrome (DS) or Lennox-Gastaut Syndrome (LGS) MedDRA version: 20.0;Level: PT;Classification ...	Trade Name: CBD - Oral Solution, is known as Epidiolex, and is the approved name in the USA. Product N ...	GW Research Ltd	NULL	Not Recruiting			Female: yes Male: yes	680	Phase 3	United States;France;Spain;Poland;Australia;Israel;Netherlands;United Kingdom

First Previous1 2 3Next Last